Endothelin inhibition: Novel therapy for prostate cancer

Joel B. Nelson, William R. Sellers, Joel B. Nelson, Matthew R. Smith, Philip W. Kantoff, Mack Roach, William K. Oh

Research output: Contribution to journalArticlepeer-review

66 Scopus citations


Purpose: Androgen refractory prostate cancer continues to evade effective treatment. The potent vasoconstrictor endothelin-1 is produced by prostate cancer and appears to have a role in prostate cancer progression and morbidity. Background on the endothelin axis (endothelin-1 and endothelin receptors ET A and ETB), preclinical studies of its role in prostate cancer, results of phases I and II clinical trials, and future directions are reviewed. Materials and Methods: A review was conducted of the published data on the endothelin axis in prostate cancer. Results: Based on preclinical and clinical trial data, the endothelin axis is emerging as potentially important in the biology of prostate cancer progression and morbidity. Drugs targeting the endothelin axis, such as the potent ETA receptor antagonist atrasentan (ABT-627), have been studied in large clinical trials and appear to have an impact on disease progression and morbidity. Conclusions: The role of the endothelin axis in prostate cancer deserves further investigation in the laboratory and clinic. This new strategy for intervention is promising.

Original languageEnglish
Pages (from-to)S65-S68
JournalJournal of Urology
Issue number6 II
StatePublished - Dec 2003


  • Clinical trial
  • Endothelin receptors
  • Endothelin-1
  • Metastases
  • Prostatic neoplasms


Dive into the research topics of 'Endothelin inhibition: Novel therapy for prostate cancer'. Together they form a unique fingerprint.

Cite this